China (Mainland)
Olaparib CAS NO.763113-22-0
- FOB Price: USD: 95.00-165.00 /Kilogram Get Latest Price
- Min.Order: 10 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T
- Available Specifications:
USP(1-10)KilogramUSP(10-1000)Kilogram
- Product Details
Keywords
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
- 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
- AZD2281(olaparib)
Quick Details
- ProName: Olaparib
- CasNo: 763113-22-0
- Molecular Formula: C24H23FN4O3
- Appearance: White to Off-White
- Application: A potentially useful antibacterial age...
- DeliveryTime: in stock
- ProductionCapacity: Metric Ton/Week
- Purity: 99%
- LimitNum: 10 Kilogram
Superiority
Breast cancer and ovarian cancer are serious public health problems that seriously threaten girls. In recent years, the incidence rate of breast cancer in China has increased by 1-2 percentage points higher than that in high-incidence countries. On the other hand, ovarian cancer is still the most serious challenge faced by gynecological oncologists, because it does not have mature early diagnosis methods, about 70% of the patients are in the advanced stage when diagnosed, even after effective treatment to achieve complete remission, 70% of patients will relapse, and the 5-year survival rate has been hovering around 30-40%. Therefore, people are trying to establish tertiary prevention and control measures for ovarian cancer like other chronic diseases.
Details
Breast cancer and ovarian cancer are serious public health problems that seriously threaten girls. In recent years, the incidence rate of breast cancer in China has increased by 1-2 percentage points higher than that in high-incidence countries. On the other hand, ovarian cancer is still the most serious challenge faced by gynecological oncologists, because it does not have mature early diagnosis methods, about 70% of the patients are in the advanced stage when diagnosed, even after effective treatment to achieve complete remission, 70% of patients will relapse, and the 5-year survival rate has been hovering around 30-40%. Therefore, people are trying to establish tertiary prevention and control measures for ovarian cancer like other chronic diseases.